All articles tagged with #intranasal delivery
Texas A&M researchers report that a two-dose intranasal spray delivering extracellular vesicles loaded with microRNAs reduced brain inflammation, restored mitochondrial function, and improved memory in animal models—hinting at a potential, noninvasive therapy for age-related cognitive decline and dementia, though human trials are not yet underway and findings are preclinical.
Texas A&M researchers report that a two-dose intranasal spray delivering extracellular vesicles with microRNAs reduced brain inflammation, recharged neuronal mitochondria, and noticeably improved memory in preclinical aging models, suggesting a noninvasive therapy for brain aging and dementia that bypasses the blood-brain barrier; the team has filed a US patent with backing from the National Institute on Aging.
Two-dose intranasal spray delivering extracellular vesicle microRNA cargo reduced brain inflammation, recharged mitochondrial function, and significantly improved memory in aging brain models within weeks—effects lasting months—which could reshape neurodegenerative therapies and offer a noninvasive alternative to invasive procedures or long-term meds, with a U.S. patent filed.
A Texas A&M–led study reports a non-invasive intranasal spray carrying extracellular vesicles and microRNA cargo can reach the brain, suppress chronic inflammation, recharge mitochondrial function, and markedly improve memory in aging models within weeks—effects persist for months after just two doses and are similar in males and females. The researchers envision potential use in stroke recovery and dementia therapy, and a U.S. patent has been filed.